ABL DiagnosticsXPAR:ABLD +0.76%51 Quick Ratio is 2.12 as of Dec. 2025, which is 86% below its 10-year median of 15.62. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 678 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 69.76% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. ABL Diagnostics's quick ratio for the quarter that ended in Dec. 2025 was 2.12.
ABL Diagnostics has a quick ratio of 2.12. It generally indicates good short-term financial strength.
The historical rank and industry rank for ABL Diagnostics's Quick Ratio or its related term are showing as below:
XPAR:ABLD'
s Quick Ratio Range Over the Past 10 Years
Min: 1.89 Med: 15.62 Max: 132.11
Current: 2.12
During the past 13 years, ABL Diagnostics's highest Quick Ratio was 132.11. The lowest was 1.89. And the median was 15.62.
XPAR:ABLD's Quick Ratio is ranked better than 69.76% of 678
companies
in the Healthcare Providers & Services industry
Industry Median: 1.325
vs XPAR:ABLD: 2.12
ABL Diagnostics (XPAR:ABLD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
ABL Diagnostics Quick Ratio Related Terms
ABL Diagnostics Quick Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: Quick Ratio Comparison
For the Health Information Services subindustry, ABL Diagnostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Quick Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
ABL Diagnostics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a Quick Ratio of 2.12 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ABL Diagnostics and its competitors. This is 86% below median its historical median of 15.62. Over the past decade, ABL Diagnostics' Quick Ratio has ranged from 1.89 to 132.11. According to the industry distribution chart, ABL Diagnostics ranks #205 out of 678 companies in the Healthcare Providers & Services industry, placing it in the top 30.2%.
Is ABL Diagnostics' Quick Ratio too high?
ABL Diagnostics' current Quick Ratio of 2.12 is 86% below median its 10-year median of 15.62. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 132.11. The Healthcare Providers & Services industry median Quick Ratio is 1.33. ABL Diagnostics' value of 2.12 is 60% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #205 out of 678 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Quick Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #205 out of 678 companies for Quick Ratio. This puts ABL Diagnostics in the upper half of its industry. The industry median Quick Ratio is 1.33. ABL Diagnostics' value of 2.12 is 60% above this benchmark. Historically, ABL Diagnostics' own Quick Ratio has ranged from 1.89 to 132.11 over the past decade. While the company's 10-year median is 15.62 vs. the industry median of 1.33, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Healthcare Providers & Services company?
The median Quick Ratio among Healthcare Providers & Services companies is 1.33, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Quick Ratio of 2.12 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Quick Ratio is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Quick Ratio is 2.12, which is 86% below median its own 10-year median of 15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current Quick Ratio is 2.12, which is 86% below median its 10-year median of 15.62 and 60% above the Healthcare Providers & Services industry median of 1.33. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Quick Ratio is 2.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Quick Ratio: 2.12 (86% below median its 10-year median of 15.62)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 60% above the Healthcare Providers & Services median (#205 of 678)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
